A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 4, 2006, Pages 384-395

  Bocci, Guido ^a   Barbara, Cecilia ^a   Vannozzi, Francesca ^a   Di Paolo, Antonello ^a   Melosi, Alessandro ^a   Barsanti, Gemma ^a   Allegrini, Giacomo ^a   Falcone, Alfredo ^a   Del Tacca, Mario ^a   Danesi, Romano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFLUOROURACIL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STOMATITIS; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; HUMANS; LEUKOCYTES, MONONUCLEAR; LINEAR MODELS; MALE; MIDDLE AGED;

EID: 33749235886     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.06.007     Document Type: Article

References (33)

1. van Kuilenburg A.B. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40 (2004) 939-950
2. Ezzeldin H., and Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 4 (2004) 181-189
3. Meta-Analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer. effect of administration schedule and prognostic factors. J Clin Oncol 16 (1998) 3537-3541
4. Grem J.L. Screening for dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 11 (2005) 5067-5068
5. Diasio R.B., and Johnson M.R. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 61 (2000) 199-203
6. Van Kuilenburg A.B., Van Lenthe H., Tromp A., Veltman P.C., and Van Gennip A.H. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 46 (2000) 9-17
7. Grem J.L., Yee L.K., Venzon D.J., Takimoto C.H., and Allegra C.J. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother Pharmacol 40 (1997) 117-125
8. Etienne M.C., Lagrange J.L., Dassonville O., Fleming R., Thyss A., Renee N., et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12 (1994) 2248-2253
9. Di Paolo A., Danesi R., Falcone A., Cionini L., Vannozzi F., Masi G., et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 12 (2001) 1301-1306
10. van Kuilenburg A.B., De Abreu R.A., and van Gennip A.H. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 40 (2003) 41-45
11. 13C-uracil breath test. Clin Cancer Res 10 (2004) 2652-2658
12. Jiang H., Lu J., Jiang J., and Hu P. Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol 44 (2004) 1260-1272
13. Gamelin E., Boisdron-Celle M., Guerin-Meyer V., Delva R., Lortholary A., Genevieve F., et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17 (1999) 1105-1112
14. Garg M.B., Sevester J.C., Sakoff J.A., and Ackland S.P. Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. J Chromatogr B Analyt Technol Biomed Life Sci 774 (2002) 223-230
15. Ciccolini J., Mercier C., Blachon M.F., Favre R., Durand A., and Lacarelle B. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J Clin Pharm Ther 29 (2004) 307-315
16. Ackland S.P., Garg M.B., and Dunstan R.H. Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography. Anal Biochem 246 (1997) 79-85
17. Bocci G., Danesi R., Di Paolo A.D., Innocenti F., Allegrini G., Falcone A., et al. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 6 (2000) 3032-3037
18. Machover D., Goldschmidt E., Chollet P., Metzger G., Zittoun J., Marquet J., et al. Treatment of advanced colorectal and gastric carcinoma with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4 (1986) 685-696
19. Johnson M.R., and Diasio R.B. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 41 (2001) 151-157
20. Bocci G., Danesi R., Allegrini G., Innocenti F., Di Paolo A., Falcone A., et al. Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. Eur J Clin Pharmacol 58 (2002) 593-595
21. Stephan F., Etienne M.C., Wallays C., Milano G., and Clergue F. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am J Med 99 (1995) 685-688
22. Collie-Duguid E.S., Etienne M.C., Milano G., and McLeod H.L. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10 (2000) 217-223
23. Milano G., Etienne M.C., Pierrefite V., Barberi-Heyob M., Deporte-Fety R., and Renee N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79 (1999) 627-630
24. Van Kuilenburg A.B., van Lenthe H., Blom M.J., Mul E.P., and Van Gennip A.H. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 79 (1999) 620-626
25. Thomas D.M., and Zalcberg J.R. 5-Fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol 25 (1998) 887-895
26. Maring J.G., Groen H.J., Wachters F.M., Uges D.R., and de Vries E.G. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 5 (2005) 226-243
27. van Kuilenburg A.B., Haasjes J., Richel D.J., Zoetekouw L., Van Lenthe H., De Abreu R.A., et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6 (2000) 4705-4712
28. Ychou M., Duffour J., Kramar A., Debrigode C., Gourgou S., Bressolle F., et al. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol 52 (2003) 282-290
29. Diasio R.B., Beavers T.L., and Carpenter J.T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81 (1988) 47-51
30. Coustere C., Mentre F., Sommadossi J.P., Diasio R.B., and Steimer J.L. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemother Pharmacol 28 (1991) 123-129
31. Haller D.G., Catalano P.J., Macdonald J.S., O'Rourke M.A., Frontiera M.S., Jackson D.V., et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23 (2005) 8671-8678
32. McLeod H.L., Sludden J., Hardy S.C., Lock R.E., Hawksworth G.M., and Cassidy J. Autoregulation of 5-fluorouracil metabolism. Eur J Cancer 34 (1998) 1623-1627
33. Reigner B., Blesch K., and Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40 (2001) 85-104